Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bryan Dirks

Showing results (1-10 of 36) with videos related to

Pageof 4
Sort By:
BMC Pharmacology & Toxicology|December 21, 2012
Efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder previously treated with amphetamines: analyses from a randomized, double-blind, multicenter, placebo-controlled titration studyThomas Babcock, Bryan Dirks, Ben Adeyi, et al.
Neuropsychiatric Disease and Treatment|February 3, 2009
Direct and indirect effects of paliperidone extended-release tablets on negative symptoms of schizophreniaIbrahim Turkoz, Cynthia A Bossie, Bryan Dirks, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 26, 2025
Drug DevelopmentMona Darwish, Xiaoshu Feng, Bryan Dirks, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 26, 2025
Drug DevelopmentMona Darwish, Bryan Dirks, Xiaoshu Feng, et al.
Alzheimer'S & Dementia (New York, N. Y.)|May 4, 2026
Population pharmacokinetics of remlifanserin (ACP-204), a serotonin 2A receptor inverse agonistMona Darwish, Nancy Lin, Bryan Dirks, et al.
Journal of Attention Disorders|January 28, 2014
Treatment With Lisdexamfetamine Dimesylate Improves Self- and Informant-Rated Executive Function Behaviors and Clinician- and Informant-Rated ADHD Symptoms in Adults: Data From a Randomized, Double-Blind, Placebo-Controlled StudyRichard Weisler, Lawrence Ginsberg, Bryan Dirks, et al.
Child and Adolescent Psychiatry and Mental Health|November 8, 2011
Efficacy of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder previously treated with methylphenidate: a post hoc analysisRakesh Jain, Thomas Babcock, Teodor Burtea, et al.
Innovations in Clinical Neuroscience|July 19, 2012
Attention deficit hyperactivity disorder subtypes and symptom response in adults treated with lisdexamfetamine dimesylateGreg Mattingly, Richard Weisler, Bryan Dirks, et al.
European Child & Adolescent Psychiatry|February 15, 2018
Long-term safety and efficacy of guanfacine extended release in children and adolescents with ADHDMichael Huss, Bryan Dirks, Joan Gu, et al.
BMC Psychiatry|October 11, 2013
Self-Reported quality of life in adults with attention-deficit/hyperactivity disorder and executive function impairment treated with lisdexamfetamine dimesylate: a randomized, double-blind, multicenter, placebo-controlled, parallel-group studyLenard A Adler, Bryan Dirks, Patrick Deas, et al.
Pageof 4

Showing results (1-10 of 36) with videos related to

Sort By:
Pageof 4
BMC Pharmacology & Toxicology|December 21, 2012
Efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder previously treated with amphetamines: analyses from a randomized, double-blind, multicenter, placebo-controlled titration studyThomas Babcock, Bryan Dirks, Ben Adeyi, et al.
Neuropsychiatric Disease and Treatment|February 3, 2009
Direct and indirect effects of paliperidone extended-release tablets on negative symptoms of schizophreniaIbrahim Turkoz, Cynthia A Bossie, Bryan Dirks, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 26, 2025
Drug DevelopmentMona Darwish, Xiaoshu Feng, Bryan Dirks, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 26, 2025
Drug DevelopmentMona Darwish, Bryan Dirks, Xiaoshu Feng, et al.
Alzheimer'S & Dementia (New York, N. Y.)|May 4, 2026
Population pharmacokinetics of remlifanserin (ACP-204), a serotonin 2A receptor inverse agonistMona Darwish, Nancy Lin, Bryan Dirks, et al.
Journal of Attention Disorders|January 28, 2014
Treatment With Lisdexamfetamine Dimesylate Improves Self- and Informant-Rated Executive Function Behaviors and Clinician- and Informant-Rated ADHD Symptoms in Adults: Data From a Randomized, Double-Blind, Placebo-Controlled StudyRichard Weisler, Lawrence Ginsberg, Bryan Dirks, et al.
Child and Adolescent Psychiatry and Mental Health|November 8, 2011
Efficacy of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder previously treated with methylphenidate: a post hoc analysisRakesh Jain, Thomas Babcock, Teodor Burtea, et al.
Innovations in Clinical Neuroscience|July 19, 2012
Attention deficit hyperactivity disorder subtypes and symptom response in adults treated with lisdexamfetamine dimesylateGreg Mattingly, Richard Weisler, Bryan Dirks, et al.
European Child & Adolescent Psychiatry|February 15, 2018
Long-term safety and efficacy of guanfacine extended release in children and adolescents with ADHDMichael Huss, Bryan Dirks, Joan Gu, et al.
BMC Psychiatry|October 11, 2013
Self-Reported quality of life in adults with attention-deficit/hyperactivity disorder and executive function impairment treated with lisdexamfetamine dimesylate: a randomized, double-blind, multicenter, placebo-controlled, parallel-group studyLenard A Adler, Bryan Dirks, Patrick Deas, et al.
Pageof 4